203 related articles for article (PubMed ID: 36845145)
1. Multi-omics analysis unravels the underlying mechanisms of poor prognosis and differential therapeutic responses of solid predominant lung adenocarcinoma.
Li F; Wang S; Wang Y; Lv Z; Jin D; Yi H; Fu L; Zhai S; Xiao T; Mao Y
Front Immunol; 2023; 14():1101649. PubMed ID: 36845145
[TBL] [Abstract][Full Text] [Related]
2. Genetic and Immune Profiles of Solid Predominant Lung Adenocarcinoma Reveal Potential Immunotherapeutic Strategies.
Dong ZY; Zhang C; Li YF; Su J; Xie Z; Liu SY; Yan LX; Chen ZH; Yang XN; Lin JT; Tu HY; Yang JJ; Zhou Q; Sun YL; Zhong WZ; Wu YL
J Thorac Oncol; 2018 Jan; 13(1):85-96. PubMed ID: 29127022
[TBL] [Abstract][Full Text] [Related]
3. The association of genomic alterations with PD-L1 expression in Chinese patients with EGFR/ALK wild-type lung adenocarcinoma and potential predictive value of Hippo pathway mutations to immunotherapy.
Liu F; Zhang X; Lu M; Liu C; Zhang X; Chu Q; Chen Y; Zhang P
Cancer Med; 2024 Feb; 13(3):e7038. PubMed ID: 38396367
[TBL] [Abstract][Full Text] [Related]
4. Combination of tumor mutation burden and immune infiltrates for the prognosis of lung adenocarcinoma.
Zhao Z; He B; Cai Q; Zhang P; Peng X; Zhang Y; Xie H; Wang X
Int Immunopharmacol; 2021 Sep; 98():107807. PubMed ID: 34175739
[TBL] [Abstract][Full Text] [Related]
5. Aggressive tumor microenvironment of solid predominant lung adenocarcinoma subtype harboring with epidermal growth factor receptor mutations.
Saruwatari K; Ikemura S; Sekihara K; Kuwata T; Fujii S; Umemura S; Kirita K; Matsumoto S; Yoh K; Niho S; Ohmatsu H; Ochiai A; Kohrogi H; Tsuboi M; Goto K; Ishii G
Lung Cancer; 2016 Jan; 91():7-14. PubMed ID: 26711928
[TBL] [Abstract][Full Text] [Related]
6. Signatures of Multi-Omics Reveal Distinct Tumor Immune Microenvironment Contributing to Immunotherapy in Lung Adenocarcinoma.
Huang Z; Li B; Guo Y; Wu L; Kou F; Yang L
Front Immunol; 2021; 12():723172. PubMed ID: 34539658
[TBL] [Abstract][Full Text] [Related]
7. Leveraging diverse cell-death patterns to predict the clinical outcome of immune checkpoint therapy in lung adenocarcinoma: Based on muti-omics analysis and vitro assay.
Liang H; Li Y; Qu Y; Zhang L
Oncol Res; 2023; 32(2):393-407. PubMed ID: 38186574
[TBL] [Abstract][Full Text] [Related]
8. [Immune Microenvironment Comparation Study between EGFR Mutant and EGFR Wild Type Lung Adenocarcinoma Patients Based on TCGA Database].
Zhu G; Li Y; Shi R; Xu S; Zhang Z; Cao P; Chen C; Liu H; Chen J
Zhongguo Fei Ai Za Zhi; 2021 Apr; 24(4):236-244. PubMed ID: 33910272
[TBL] [Abstract][Full Text] [Related]
9. A lepidic gene signature predicts patient prognosis and sensitivity to immunotherapy in lung adenocarcinoma.
Nguyen TT; Lee HS; Burt BM; Wu J; Zhang J; Amos CI; Cheng C
Genome Med; 2022 Jan; 14(1):5. PubMed ID: 35016696
[TBL] [Abstract][Full Text] [Related]
10. Potential Predictive Value of
Dong ZY; Zhong WZ; Zhang XC; Su J; Xie Z; Liu SY; Tu HY; Chen HJ; Sun YL; Zhou Q; Yang JJ; Yang XN; Lin JX; Yan HH; Zhai HR; Yan LX; Liao RQ; Wu SP; Wu YL
Clin Cancer Res; 2017 Jun; 23(12):3012-3024. PubMed ID: 28039262
[No Abstract] [Full Text] [Related]
11. Single-cell transcriptome analysis revealed a suppressive tumor immune microenvironment in EGFR mutant lung adenocarcinoma.
Yang L; He YT; Dong S; Wei XW; Chen ZH; Zhang B; Chen WD; Yang XR; Wang F; Shang XM; Zhong WZ; Wu YL; Zhou Q
J Immunother Cancer; 2022 Jan; 10(2):. PubMed ID: 35140113
[TBL] [Abstract][Full Text] [Related]
12. Identification of immune activation-related gene signature for predicting prognosis and immunotherapy efficacy in lung adenocarcinoma.
Zeng W; Wang J; Yang J; Chen Z; Cui Y; Li Q; Luo G; Ding H; Ju S; Li B; Chen J; Xie Y; Tong X; Liu M; Zhao J
Front Immunol; 2023; 14():1217590. PubMed ID: 37492563
[TBL] [Abstract][Full Text] [Related]
13. Specific TP53 subtype as biomarker for immune checkpoint inhibitors in lung adenocarcinoma.
Sun H; Liu SY; Zhou JY; Xu JT; Zhang HK; Yan HH; Huan JJ; Dai PP; Xu CR; Su J; Guan YF; Yi X; Yu RS; Zhong WZ; Wu YL
EBioMedicine; 2020 Oct; 60():102990. PubMed ID: 32927274
[TBL] [Abstract][Full Text] [Related]
14. Comprehensive analysis of the immunogenic cell death-related signature for predicting prognosis and immunotherapy efficiency in patients with lung adenocarcinoma.
Cui Y; Li Y; Long S; Xu Y; Liu X; Sun Z; Sun Y; Hu J; Li X
BMC Med Genomics; 2023 Aug; 16(1):184. PubMed ID: 37553698
[TBL] [Abstract][Full Text] [Related]
15. Molecular classification reveals the sensitivity of lung adenocarcinoma to radiotherapy and immunotherapy: multi-omics clustering based on similarity network fusion.
Zhang J; Li Y; Dai W; Tang F; Wang L; Wang Z; Li S; Ji Q; Zhang J; Liao Z; Yu J; Xu Y; Gong J; Hu J; Li J; Guo X; He F; Han L; Gong Y; Ouyang W; Wang Z; Xie C
Cancer Immunol Immunother; 2024 Mar; 73(4):71. PubMed ID: 38430394
[TBL] [Abstract][Full Text] [Related]
16. An aging-related signature predicts favorable outcome and immunogenicity in lung adenocarcinoma.
Zhang W; Li Y; Lyu J; Shi F; Kong Y; Sheng C; Wang S; Wang Q
Cancer Sci; 2022 Mar; 113(3):891-903. PubMed ID: 34967077
[TBL] [Abstract][Full Text] [Related]
17. CD8
Zhang M; Ma J; Guo Q; Ding S; Wang Y; Pu H
Front Immunol; 2022; 13():806877. PubMed ID: 35273597
[TBL] [Abstract][Full Text] [Related]
18. Vasculogenic mimicry-associated novel gene signature predicted prognosis and response to immunotherapy in lung adenocarcinoma.
Zhang L; Wu J; Yin WW; Hu J; Liao L; Ma J; Xu Z; Wu S
Pathol Res Pract; 2024 Jan; 253():155048. PubMed ID: 38147724
[TBL] [Abstract][Full Text] [Related]
19. [Correlation between Immune Microenvironment Features and EGFR Mutation Status
in Lung Adenocarcinoma].
Zhu H; Chen P; Dong G; Meng F; Xia Z; You J; Kong X; Wu J; Yuan F; Yu X; Sun Q; Ji J; Wang S; Liu T; Xu L
Zhongguo Fei Ai Za Zhi; 2023 Mar; 26(3):204-216. PubMed ID: 37035883
[TBL] [Abstract][Full Text] [Related]
20. PD-L1 expression and T cells infiltration in patients with uncommon EGFR-mutant non-small cell lung cancer and the response to immunotherapy.
Chen K; Cheng G; Zhang F; Zhu G; Xu Y; Yu X; Huang Z; Fan Y
Lung Cancer; 2020 Apr; 142():98-105. PubMed ID: 32120230
[TBL] [Abstract][Full Text] [Related]
[Next] [New Search]
